1. Home
  2. VMD vs CRDF Comparison

VMD vs CRDF Comparison

Compare VMD & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Viemed Healthcare Inc.

VMD

Viemed Healthcare Inc.

N/A

Current Price

$9.28

Market Cap

313.3M

Sector

N/A

ML Signal

N/A

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

N/A

Current Price

$2.00

Market Cap

130.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VMD
CRDF
Founded
2006
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
313.3M
130.7M
IPO Year
2018
2012

Fundamental Metrics

Financial Performance
Metric
VMD
CRDF
Price
$9.28
$2.00
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$9.63
AVG Volume (30 Days)
189.1K
678.6K
Earning Date
06-09-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
32.14
27.37
EPS
0.37
N/A
Revenue
$270,280,000.00
$365,993.00
Revenue This Year
$22.48
N/A
Revenue Next Year
$22.28
N/A
P/E Ratio
$23.68
N/A
Revenue Growth
20.52
49.61
52 Week Low
$5.93
$1.48
52 Week High
$9.20
$4.56

Technical Indicators

Market Signals
Indicator
VMD
CRDF
Relative Strength Index (RSI) 67.08 54.74
Support Level $8.05 $1.99
Resistance Level N/A $2.05
Average True Range (ATR) 0.35 0.13
MACD 0.02 0.06
Stochastic Oscillator 99.39 92.08

Price Performance

Historical Comparison
VMD
CRDF

About VMD Viemed Healthcare Inc.

Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

Share on Social Networks: